5231-89-0 Usage
Uses
Used in Organic Synthesis:
3,4-DIAMINOCYCLOBUT-3-ENE-1,2-DIONE is used as a versatile building block for the synthesis of a variety of functionalized heterocyclic compounds. Its unique structure allows for the creation of complex molecules that can be utilized in various chemical applications.
Used in Pharmaceutical Development:
Due to its interesting reactivity and structural properties, 3,4-DIAMINOCYCLOBUT-3-ENE-1,2-DIONE is employed in the development of novel pharmaceuticals. Its potential use in medicinal chemistry is attributed to its ability to form the basis of new drug candidates with unique mechanisms of action.
Used in Material Science:
3,4-DIAMINOCYCLOBUT-3-ENE-1,2-DIONE also has potential applications in material science, where its unique structure and reactivity can contribute to the development of new materials with specific properties for various industries.
Used in Research and Education:
As a useful tool in the study of organic chemistry, 3,4-DIAMINOCYCLOBUT-3-ENE-1,2-DIONE is utilized in research laboratories and educational settings to explore chemical reactions and mechanisms, furthering the understanding of organic chemistry principles and their applications.
Check Digit Verification of cas no
The CAS Registry Mumber 5231-89-0 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 5,2,3 and 1 respectively; the second part has 2 digits, 8 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 5231-89:
(6*5)+(5*2)+(4*3)+(3*1)+(2*8)+(1*9)=80
80 % 10 = 0
So 5231-89-0 is a valid CAS Registry Number.
InChI:InChI=1/C4H4N2O2/c5-1-2(6)4(8)3(1)7/h5-6H2
5231-89-0Relevant academic research and scientific papers
KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF
-
Paragraph 00206, (2013/03/28)
Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.
Amino substituted bisketenes: Generation, structure, and reactivity
Fu, Nanyan,Allen, Annette D.,Kobayashi, Shinjiro,Tidwell, Thomas T.,Vukovic, Sinisa,Arumugam, Selvananthan,Popik, Vladimir V.,Mishima, Masaaki
, p. 1951 - 1956 (2007/10/03)
Hitherto unknown diamino-substituted bisketenes with both free (14) and tethered (16) amino substituents have been generated by using laser flash photolysis for ring opening of the corresponding cyclobutenediones. The time-resolved kinetics of ring closur
